Skip to main content
CHGCF logo

Chugai Pharmaceutical Co., Ltd. (CHGCF) Stock Price & Analysis

Chugai Pharmaceutical Co., Ltd. (CHGCF) — price $44.52 (-2.84%), as of the Nov 19, 2026 trading session; market cap $73.3B.

Educational signal · not a buy or sell recommendation · How to read this

$44.52 −$1.30 (-2.84%) Market Cap $73.3B

Chugai Pharmaceutical Co., Ltd. · CHGCF · Healthcare · Drug Manufacturers - General

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • GSK · GSK plc · 77 /100
  • SNY · Sanofi · 87 /100
  • BMY · Bristol-Myers Squibb Company · 85 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$44.52
Change on the day-2.84%
52-week range$34.79–$68.08
Market capitalisation$73.3B—
Price / earnings (trailing)23.64
Shares traded on the day1.9K
Beta (volatility vs the S&P 500)0.55

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $38, high $68, latest $45. $68 $38 high $68 Oct 17, 2025 Nov 19, 2026 · $45 $49Oct 17, 2025$45Oct 31, 2025$52Nov 14, 2025$55Nov 28, 2025$55Dec 12, 2025$54Dec 26, 2025$53Jan 9, 2026$55Jan 23, 2026$57Feb 6, 2026$62Feb 20, 2026$59Mar 6, 2026$52Mar 20, 2026$56Apr 2, 2026$54Apr 17, 2026$53May 1, 2026$49May 15, 2026$48May 29, 2026$45Jun 12, 2026$47Jun 26, 2026$45Jul 10, 2026$48Jul 24, 2026$43Aug 7, 2026$42Aug 21, 2026$43Sep 4, 2026$42Sep 18, 2026$38Oct 2, 2026$40Oct 16, 2026$42Oct 30, 2026$46Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Chugai Pharmaceutical Co. (CHGCF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Strong
ROE Strong
Gross Margin Strong

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Chugai Pharmaceutical Co. (CHGCF), and what does it report?

Short answer

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. Healthcare / Drug Manufacturers General Headquarters: Nihonbashi Mitsui Tower, Tokyo, TY, 103-8324, JP. It employs 7,872 people. The market values it at $73.3B.

3 · Financial strengths and risks

What are the financial strengths and risks for Chugai Pharmaceutical Co. (CHGCF)?

Short answer

The distress and quality screens read Altman Z 28.59 · Piotroski F 7. Trailing ratios: ROE 25.3% · ROA 18.7% · current ratio 6.39.

4 · What to check next?

What should you watch next at Chugai Pharmaceutical Co. (CHGCF)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $1.37T · EPS 304.35 · 14 analysts.

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$1.37T
EPS estimate
$304.35

Measured against a quoted price of $44.52 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CHGCF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported CHGCF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Chugai Pharmaceutical Co. (CHGCF)?

Read these with our analysis →

What Investors Ask About Chugai Pharmaceutical Co. (CHGCF) — Healthcare

These answers are editorial: 1 of these 8 answers is drawn from the CHGCF research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is CHGCF a good stock to buy?

Stock Expert AI does not rate CHGCF buy, sell or hold. Chugai Pharmaceutical Co., Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CHGCF stock price today?

The last price recorded for Chugai Pharmaceutical Co., Ltd. (CHGCF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the implications of CHGCF trading on the OTC market for investors?

CHGCF's trading on the 'OTC Other' tier of the OTC market carries several implications for investors. Primarily, the 'Unknown' disclosure status means that public access to timely and comprehensive financial information, such as quarterly reports or annual statements in English, may be limited.

What are the key factors to evaluate for CHGCF?

Evaluate CHGCF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Expanding its R&D efforts and product launches in this segment could unlock substantial growth. Not financial advice.

How frequently does CHGCF data refresh on this page?

CHGCF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CHGCF's recent stock price performance?

Chugai Pharmaceutical Co., Ltd. (CHGCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong strategic alliance with Roche Group providing global R&D and market access. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CHGCF overvalued or undervalued right now?

The trailing P/E of Chugai Pharmaceutical Co., Ltd. (CHGCF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research CHGCF before investing?

Before investing in Chugai Pharmaceutical Co., Ltd. (CHGCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 19 figures on this page — 12 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.